Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Mid-range Performer

2072.9000 1.50 (0.07%)

NSE May 15, 2025 15:31 PM

38.81% Gain from 52W Low

Volume: 2.3M

Lupin Ltd.

09 Nov 2024

2072.90

0.07%

Lupin (BUY): In-line quarter; EBITDAM guidance increased to 25%

Buy: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

LPC's earnings were in line with our estimates but beat street's estimates. EBITDA margin was 23% in Q2FY25

Lupin Ltd. has an average target of 2329.44 from 9 brokers.